CLNN Clene Inc

Clene to Present at the Canaccord Genuity 43rd Annual Growth Conference

Clene to Present at the Canaccord Genuity 43rd Annual Growth Conference

SALT LAKE CITY, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, today announced that it will present at the Canaccord Genuity 43rd Annual Growth Conference. Rob Etherington, Chief Executive Officer, and Morgan Brown, Chief Financial Officer, will participate in the presentation and investor meetings.

Date: August 10, 2023

Location: InterContinental Hotel, Boston

Time and Location of Presentation: 11:30 a.m. EDT, Eleanor/Dartmouth Rooms

Format: Corporate presentation and 1x1 meetings

A webcast of the presentation will be available on the “” section of the Clene website. Alternatively, one can register online to view the webcast here: .

About Clene

Clene is a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease by targeting energetic failure, an underlying cause of many neurological diseases. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit or follow us on , and

Contacts:

Media Contact

Ignacio Guerrero-Ros, Ph.D., or David Schull

Russo Partners, LLC

I 

 

(858) 717-2310		 Investor Contact

Kevin Gardner

LifeSci Advisors



617-283-2856



EN
02/08/2023

Underlying

CLNNClene Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Clene Inc

 PRESS RELEASE
Free
CLNN CLENE INC

Clene Issues Stockholder Letter Highlighting Upcoming CNM-Au8® 2026 C...

Clene Issues Stockholder Letter Highlighting Upcoming CNM-Au8® 2026 Catalysts Operating capital runway sufficient into the fourth quarter of 2026 In-person Type C FDA meeting scheduled by end of the first quarter of 2026 to discuss the latest CNM-Au8 data submitted in late 2025Anticipated submission of a New Drug Application (NDA) to FDA for CNM-Au8 via an accelerated regulatory pathway in the second quarter of 2026Potential for FDA acceptance of this NDA and issuance of a Prescription Drug User Fee Act (PDUFA) date in the second half of 2026 SALT LAKE CITY, Feb. 24, 2026 (GLOBE NEWSWIR...

February 24, 2026 1 EN
 PRESS RELEASE
Free
CLNN CLENE INC

Clene to Present at the Emerging Growth Conference

Clene to Present at the Emerging Growth Conference SALT LAKE CITY, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Emerging Growth Conference. Virtual Presentation DetailsDate: February 25, 2026Time of Pr...

February 19, 2026 1 EN
 PRESS RELEASE
Free
CLNN CLENE INC

Clene to Present at the Emerging Growth Conference

Clene to Present at the Emerging Growth Conference SALT LAKE CITY, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Emerging Growth Conference. Virtual Presentation DetailsDate: January 21, 2026Time of Pre...

January 16, 2026 1 EN
 PRESS RELEASE
Free
CLNN CLENE INC

Clene Announces Additional CNM-Au8 Biomarker Data Supporting Potential...

Clene Announces Additional CNM-Au8 Biomarker Data Supporting Potential NDA Filing for Upcoming In-Person FDA Meeting The FDA has granted an in-person Type C meeting during the first quarter of 2026 New independent analyses across large observational ALS cohorts demonstrate that modest (~10%) NfL reductions are significantly associated with lower mortality risk, supporting NfL reduction as a candidate surrogate endpoint for accelerated approvalNew exploratory findings demonstrate that in responders with IGFBP7 biomarker decline, CNM-Au8 30mg was strongly associated with 78% reduced mortality...

January 12, 2026 1 EN
 PRESS RELEASE
Free
CLNN CLENE INC

Clene Announces Registered Direct Offering of Over $28 Million

Clene Announces Registered Direct Offering of Over $28 Million Oversubscribed registered direct offering priced above market to new, existing and insider investors, including Boxer Capital Management, Coastlands Capital, and Vivo CapitalInitial financing tranche of over $6 million, which we expect will provide cash runway into the third quarter of 2026 enabling funding through potential NDA acceptance decision by the FDA, with two additional financing tranches totaling over $22 million contingent on NDA acceptance and NDA approval by the FDACompletion of this financing through its three tra...

January 9, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch